Gladstone Institutional Advisory LLC Clovis Oncology, Inc. Transaction History

Gladstone Institutional Advisory LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $89,319 - $127,600	-22,000 Closed	0 $0
Q2 2021 Jan 27, 2023	SELL	$5.02 - $7.05 $196,281 - $275,655	-39,100 Reduced 63.99%	22,000 $128,000
Q2 2021 Aug 13, 2021	BUY	$5.02 - $7.05 $110,439 - $155,100	22,000 New	22,000 $128,000
Q4 2020 Feb 16, 2021	SELL	$4.13 - $6.41 $252,343 - $391,651	-61,100 Closed	0 $0
Q3 2020 Jan 27, 2023	BUY	$4.82 - $7.72 $294,502 - $471,692	61,100 New	61,100 $356,000
Q3 2020 Nov 16, 2020	BUY	$4.82 - $7.72 $219,440 - $351,468	45,527 Added 292.35%	61,100 $356,000
Q2 2020 Aug 17, 2020	BUY	$5.69 - $9.69 $88,610 - $150,902	15,573 New	15,573 $105,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Gladstone Institutional Advisory LLC, based on Form 13F filings with the SEC.

Stay updated on Gladstone Institutional Advisory LLC with notifications on news.